Hospital protocols and evidence-based therapies: The importance of integrating aldosterone blockade into the management of patients with post-acute myocardial infarction heart failure

Clinical Cardiology

Volumn 29, Issue 1, 2006, Pages 4-8

  Fonarow, Gregg C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acute myocardial infarction; Aldosterone blockade; Critical pathways; Eplerenone; Heart failure

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPLERENONE; FIBRINOLYTIC AGENT; HEPARIN; PLACEBO; RAMIPRIL; SPIRONOLACTONE; TRANDOLAPRIL;

ACUTE HEART INFARCTION; CLINICAL PATHWAY; CLINICAL PROTOCOL; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DRUG COST; DRUG EFFICACY; DRUG INDICATION; EVIDENCE BASED MEDICINE; FOLLOW UP; HEALTH CARE QUALITY; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HIGH RISK POPULATION; HOSPITAL CARE; HUMAN; HYPERKALEMIA; KIDNEY FUNCTION; MEDICAL SOCIETY; META ANALYSIS; MORBIDITY; MORTALITY; PATIENT MONITORING; POTASSIUM BLOOD LEVEL; REVIEW; ST SEGMENT ELEVATION; SURVIVAL; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; ALDOSTERONE ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CRITICAL PATHWAYS; EVIDENCE-BASED MEDICINE; HEART FAILURE, CONGESTIVE; HUMANS; MYOCARDIAL INFARCTION; VENTRICULAR DYSFUNCTION, LEFT;

EID: 31144438555     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.4960290103     Document Type: Review

References (29)

1. Hasdai D, Topol EJ, Kilaru R, Battler A, Harrington RA, Vahanian A, Ohman EM, Granger CB, Van de Werf F, Simoons ML, O'Connor CM, Holmes DR Jr: Frequency, patient characteristics, and outcomes of mild-to-moderate heart failure complicating ST-segment elevation acute myocardial infarction: Lessons from 4 international fibrinolytic therapy trials. Am Heart J 2003;145:73-79
2. Steg PG, Dabbous OH, Feldman LJ, Cohen-Solal A, Aumont MC, Lopez-Sendon J, Budaj A, Goldberg RJ, Klein W, Anderson FA Jr: Determinants and prognostic impact of heart failure complicating acute coronary syndromes. Circularion 2004;109:494-499
3. Wu AH, Parsons L, Every NR, Bates ER: Hospital outcomes in patients presenting with congestive heart failure complicating acute myocardial infarction. A report from the second national registry of myocardial infarction (NRMI-2). J Am Coll Cardiol 2002;40:1389-1394
4. Pelliccia F, Cartoni D, Verde M, Salvini P, Mercuro G, Tanzi P: Critical pathways in the emergency department improve treatment modalities for patients with ST-elevation myocardial infarction in a European hospital. Clin Cardiol 2004;27:698-700
5. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, Hochman JS, Krumholz HM, Kushner FG, Lamas GA, Mullany CJ, Ornato JP, Pearle DL, Sloan MA, Smith SC Jr: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: Executive summary: A report of the ACC/AHA Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines on the Management of Patients with Acute Myocardial Infarction). Circulation 2004;110:588-636
6. Bestul MB, McCollum M, Stringer KA, Burchenal J: Impact of a critical pathway on acute myocardial infarction quality indicators. Pharmacotherapy 2004;24:173-178
7. Fonarow GC, French WJ, Parsons LS, Sun H, Malmgren JA, for the National Registry of Myocardial Infarction 3 Participants: Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: Data from the National Registry of Myocardial Infarction 3. Circulation 2001;103:38-44
8. Spencer FA, Meyer TE, Gore JM, Goldberg RJ: Heterogeneity in the management and outcomes of patients with acute myocardial infarction complicated by heart failure: The National Registry of Myocardial Infarction. Circulation 2002;105:2605-2610
9. Fonarow GC, Gawlinski A, Moughrabi S, Tillisch JH: Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). Am J Cardiol 2001;87:819-822
10. Saint S, Hofer TP, Rose JS, Kaufman SR, McMahon LF Jr: Use of critical pathways to improve efficiency: A cautionary tale. Am J Manag Care 2003;9:758-765
11. Panella M, Marchisio S, Di Stanislao F: Reducing clinical variations with clinical pathways: Do pathways work? Int J Qual Health Care 2003;15:509-521
12. Wolff AM, Taylor SA, McCabe JF: Using checklists and reminders in clinical pathways to improve hospital inpatient care. Med J Aust 2004;181:428-431
13. Mehta RH, Das S, Tsai TT, Nolan E, Kearly G, Eagle KA: Quality improvement initiative and its impact on the management of patients with acute my-ocardial infarction. Arch Intern Med 2000;160:3057-3062
14. Butler J, Arbogast PG, BeLue R, Daugherty J, Jain MK, Ray WA, Griffin MR: Outpatient adherence to beta-blocker therapy after acute myocardial infarction. J Am Coll Cardiol 2002;40:1589-1595
15. Butler J, Arbogast PG, Daugherty J, Jain MK, Ray WA, Griffin MR: Outpatient utilization of angiotensin-converting enzyme inhibitors among heart failure patients after hospital discharge. J Am Coll Cardiol 2004;43:2036-2043
16. Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, Torp-Pedersen C, Ball S, Pogue J, Moyé L, Braunwald E: Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: A systematic overview of data from individual patients. ACE-inhibitor Myocardial Infarction Collaborative Group. Lancet 2000;355:1575-1581
17. Chadda K, Goldstein S, Byington R, Curb JD: Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation 1986;73:503-510
18. Dargie HJ: The CAPRICORN Investigators: Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: The CAPRICORN randomized trial. Lancet 2001;357:1385-1390
19. Doughty RN, Whalley GA, Gamble G, MacMahon S, Sharpe N: Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group. J Am Coll Cardiol 1997;29:1060-1066
20. Suzuki G, Monta H, Mishima T, Sharov VG, Todor A, Tanhehco EJ, Rudolph AE, McMahon EG, Goldstein S, Sabbah HN: Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. Circulation 2002;106:2967-2972
21. Hayashi M, Tsutamoto T, Wada A, Tsutsui T, Ishii C, Ohno K, Fujii M, Taniguchi A, Hamatani T, Nozato Y, Kataoka K, Morigami N, Ohnishi M, Kinoshita M, Horie M: Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation 2003;107:2559-2565
22. Yee KM, Pringle SD, Struthers AD: Circadian variation in the effects of aldosterone blockade on heart rate variability and QT dispersion in congestive heart failure. J Am Coll Cardiol 2001;37:1800-1807
23. Bauersachs J, Heck M, Fraccarollo D, Hildemann SK, Ertl G, Wehling M, Christ M: Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: Role of vascular superoxide anion formation and endothelial nitric oxide synthase expression. J Am Coll Cardiol 2002;39:351-358
24. Rocha R, Rudolph AE, Frierdich GE, Nachowiak DA, Kekec BK, Blomme EA, McMahon EG, Delyani JA: Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 2002;283:H1802-H1810
25. Sawathiparnich P, Kumar S, Vaughan DE, Brown NJ: Spironolactone abolishes the relationship between aldosterone and plasminogen activator inhibitor-1 in humans. J Clin Endocrinol Metab 2002;87:448-452
26. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M, for the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-1321
27. Pitt B, White H, Nicolau J, Martinez F, Gheorghiade M, Aschermann M, van Veldhuisen DJ, Zannad F, Krum H, Mukherjee R, Vincent J, on behalf of the EPHESUS Investigators: Eplerenone reduces mortality 30 days postrandomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol 2005;46:425-431
28. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-717
29. Weintraub WS, Zhang Z, Mahoney EM, Kolm P, Spertus JA, Caro J, Ishak J, Goldberg R, Tooley J, Willke R, Pitt B: Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure. Circulation 2005;111:1106-1113